Curis Inc. (CRIS) Stock Rating Upgraded by Zacks Investment Research
Curis Inc. (NASDAQ:CRIS) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.
According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “
Other analysts have also recently issued reports about the company. FBR & Co reiterated a “buy” rating on shares of Curis in a research report on Monday, June 13th. Robert W. Baird reiterated an “outperform” rating and set a $7.00 price target on shares of Curis in a research report on Friday, June 3rd. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.56.
Curis (NASDAQ:CRIS) traded up 4.46% during midday trading on Monday, reaching $2.11. 1,494,886 shares of the company traded hands. The stock’s market capitalization is $273.19 million. The firm has a 50-day moving average of $1.75 and a 200-day moving average of $1.72. Curis has a 1-year low of $1.25 and a 1-year high of $3.18.
Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($0.09) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.09). Curis had a negative return on equity of 65.51% and a negative net margin of 526.72%. The firm earned $1.70 million during the quarter, compared to analysts’ expectations of $2.05 million. During the same period in the previous year, the business earned ($0.06) earnings per share. The firm’s revenue for the quarter was down 19.0% on a year-over-year basis. On average, analysts predict that Curis will post ($0.38) earnings per share for the current year.
In related news, major shareholder Discovery Technologie Aurigene bought 10,208,333 shares of the company’s stock in a transaction on Wednesday, September 7th. The stock was bought at an average cost of $2.40 per share, for a total transaction of $24,499,999.20. Following the acquisition, the insider now directly owns 27,328,464 shares in the company, valued at $65,588,313.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.09% of the stock is owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. BlackRock Fund Advisors raised its position in shares of Curis by 1.3% in the first quarter. BlackRock Fund Advisors now owns 4,555,408 shares of the company’s stock valued at $7,334,000 after buying an additional 57,624 shares during the period. State Street Corp raised its position in shares of Curis by 5.4% in the first quarter. State Street Corp now owns 1,452,409 shares of the company’s stock valued at $2,341,000 after buying an additional 73,759 shares during the period. Geode Capital Management LLC raised its position in shares of Curis by 2.5% in the first quarter. Geode Capital Management LLC now owns 772,054 shares of the company’s stock valued at $1,243,000 after buying an additional 18,476 shares during the period. Jacobs Levy Equity Management Inc. acquired a new position in shares of Curis during the first quarter valued at approximately $248,000. Finally, Royal Bank of Canada raised its position in shares of Curis by 4.0% in the first quarter. Royal Bank of Canada now owns 803,909 shares of the company’s stock valued at $1,294,000 after buying an additional 30,894 shares during the period. 52.36% of the stock is currently owned by institutional investors and hedge funds.
Curis, Inc is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.